Skip to main content
. Author manuscript; available in PMC: 2013 Oct 22.
Published in final edited form as: Am J Gastroenterol. 2009 Jan 27;104(2):444–453. doi: 10.1038/ajg.2008.120

Table 5.

Proportion seroprotected at post-vaccination among patients who were seronegative [hemagglutination inhibition (HAI) < 10] at entry

Group A/H1N1
#/total (%)		 A/H3N2
#/total (%)		 B
#/total (%)
Non-immunosuppressed 3/3 (100%) 0/1 (0%) 3/11 (27%)
Immunosuppressed 14/19 (74%) 10/17 (59%) 13/50 (26%)
 Tacrolimus All seropositive at baseline 1/1 (100%) 0/2 (0%)
 TNF-alpha inhibitor 2/5 (40%) 3/8 (38%) 2/21 (10%)
 Immunomodulator 10/11 (91%) 4/6 (67%) 9/24 (38%)
 Corticosteroids only 2/3 (67%) 2/2 (100%) 2/3 (67%)

At post-vaccination, the proportion seroprotected was similar between the NIS and IS groups for all three influenza strains (p>0.44 for all strains): A/H1N1 (NIS 100%, IS 74%), A/H3N2 (NIS 0%, IS 59%), and B (NIS 27%, IS 26%).